関連する実験動画
Updated: Jun 21, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
MTHFR 677C-->T多形性と冠動脈疾患のリスク:メタ解析
Mariska Klerk1, Petra Verhoef, Robert Clarke
1Division of Human Nutrition and Epidemiology, Wageningen University, PO Box 8129, 6700 EV Wageningen, The Netherlands.
JAMA
|October 22, 2002
まとめ
MTHFR 677 TT遺伝子型は,冠動脈性心疾患 (CHD) のリスクを高め,特に葉酸が低い場合です. これは,ホモシステインとCHDリスクの上昇を引き起こす葉酸代謝障害をサポートします.
科学分野:
- 遺伝学と心血管伝染病学
- 栄養ゲノミクスについて
- メタボリック障害 メタボリック障害
背景:
- 血ホモシステインの値上昇は,冠動脈疾患 (CHD) のリスクの増加と関連しています.
- MTHFR677C-->Tポリモルフィズムが葉酸代謝とホモシステインレベルに影響するが,心臓病リスクにおけるその役割は不明である.
研究 の 目的:
- 観察研究から得られた個々の参加者のデータをメタ分析する.
- MTHFR 677C-->TポリモルフィズムとCHDリスクとの関連性を評価する.
主な方法:
- 関連するケース・コントロール研究のための電子文献と参照リストを検索した.
- MTHFR 677C-->T遺伝子型データを用いた40件の研究 (11,162例,12,758対照群) を含む.
- 分析されたゲノタイプ,症例対照状態,およびホモシステイン/葉酸塩のレベルは,ロジスティック回帰を用いた.
主要な成果:
- MTHFR 677 TT遺伝子型を持つ個人は,心臓病の確率が16%高かった (OR,1.16;95%CI,1.05〜1.28).
- ヨーロッパと北米の人口の間で顕著な異質性が観察されました.
- 葉酸の状態は,MTHFRポリモルフィズムが心血管疾患リスクに及ぼす影響と相互作用する可能性が高い.
結論:
- MTHFR 677 TT遺伝子型は,特に葉酸の状態が低い場合に,著しく高いCHDリスクと関連しています.
- 研究結果は,葉酸代謝障害,ホモシステイン値上昇,心臓病のリスク増加との因果関係を支持しています.
関連する概念動画
01:31Translation
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
01:31Translation
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...